Uncategorized
Glaukos Corporation Announces Fourth Quarter and Full Year 2019 Financial Results
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2019. Key highlights include: Achieved 22% net sales growth to $65.8 million in the fourth quarter of 2019, compared to $54.1 million in the fourth quarter of 2018. Achieved 31%